Spyre Therapeutics (SYRE) Financials

Spyre Therapeutics (NASDAQ: SYRE) remains a development-stage biotechnology company with no meaningful commercial revenue, but its balance sheet strengthened considerably in the second quarter of 2026. The company reported zero revenue in Q2 2026, consistent with the recent quarters, while continuing to fund research and development activities through equity financing and investment income.

• Liquidity expanded sharply. Cash and equivalents increased to $162.0 million in Q2 2026 from $97.2 million in Q1, while short-term investments rose to $983.3 million from $644.3 million. Combined cash and short-term investments reached approximately $1.15 billion.
• The balance sheet has substantial near-term financial flexibility. Total current assets of $1.17 billion compared with total current liabilities of $63.3 million, implying a current ratio of roughly 18.5. Total liabilities were only $71.9 million, or about 6% of total assets.
• Recent financing activity materially increased available capital. Spyre generated $432.6 million from financing activities in Q2 2026, including $455.8 million from common-equity issuance. This followed $312.8 million of financing proceeds in Q4 2025 and $12.3 million in Q1 2026.
• Quarterly net losses improved sequentially. Q2 2026 net loss was $36.2 million, compared with a $69.0 million loss in Q1 2026. The improvement was helped by $10.1 million of interest and investment income and a $40.0 million favorable other operating item.
• Net losses are generally lower than the largest losses reported in the earlier period. The Q2 2026 loss compares with losses of $62.5 million in Q4 2025 and $69.0 million in Q3 2024. However, quarterly results remain volatile because of nonrecurring and noncash items.
• Research spending continues to rise. Research and development expense increased to $65.5 million in Q2 2026 from $60.4 million in Q1 and $44.6 million in Q4 2025. This reflects greater investment in the pipeline, but it also increases the company’s cash requirements.
• Investment income is an increasingly important offset to operating losses. Interest and investment income grew to $10.1 million in Q2 2026 from $7.0 million in Q1. This benefit depends on the size of Spyre’s cash and investment portfolio and prevailing interest rates rather than product revenue.
• Spyre has not established a commercial revenue base. Reported revenue was zero in Q2 2026 and in the preceding quarters provided, leaving the company dependent on financing and investment returns to support operations.
• Operating cash burn worsened in the latest quarter. Net cash used in operating activities increased to $69.9 million in Q2 2026 from $57.4 million in Q1, $44.6 million in Q4 2025 and $37.1 million in Q3 2025. At the Q2 pace, annualized operating cash use would be approximately $280 million, although quarterly spending can fluctuate.
• Equity financing creates dilution risk. Common stock increased to $2.19 billion in Q2 2026 from $1.71 billion in Q1 and $1.36 billion in Q3 2025. Weighted-average basic shares reported for Q2 2026 were approximately 85.1 million, compared with 64.4 million in Q4 2025; future capital raises could further reduce existing shareholders’ ownership percentage.

Overall, Spyre’s financial position is considerably stronger than it was in 2022 and early 2023, when total assets were below $250 million and the company reported much smaller cash balances. The company now has a large investment portfolio and limited liabilities, but the improvement has been funded primarily through equity issuance. For investors, the key issues remain whether Spyre can convert its research spending into clinical and regulatory progress, control its rising cash burn, and eventually generate product revenue before additional financing becomes necessary.